Evidence map›Paper›PMID 31961100›Full record

ArticleCellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology2020

Genistein Represses HOTAIR/Chromatin Remodeling Pathways to Suppress Kidney Cancer.

Mitsuho Imai-Sumida, Pritha Dasgupta, Priyanka Kulkarni, Marisa Shiina, Yutaka Hashimoto, Varahram Shahryari, Shahana Majid, Yuichiro Tanaka, Rajvir Dahiya, Soichiro Yamamura

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 24 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 1 synthesis or guideline pooled it, 48 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Genistein in the Treatment of Hypertension: A Review.Endocrine, metabolic & immune disorders drug targets · 2022
    Review
  16. Review
  17. Review
  18. Long noncoding RNACell adhesion & migration · 2021
    Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Mitsuho Imai-SumidaDepartment of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, USA.
Pritha DasguptaDepartment of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, USA.
Priyanka KulkarniDepartment of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, USA.
Marisa ShiinaDepartment of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, USA.
Yutaka HashimotoDepartment of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, USA.
Varahram ShahryariDepartment of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, USA.
Shahana MajidDepartment of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, USA.
Yuichiro TanakaDepartment of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, USA.
Rajvir DahiyaDepartment of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, USA.
Soichiro YamamuraDepartment of Urology, San Francisco Veterans Affairs Medical Center and University of California San Francisco, San Francisco, USA, soichiro.yamamura@ucsf.edu.
San Francisco VA Medical Center · USUniversity of California, San Francisco · US

Funding

MicroRNAs in the Progression and Metastisis of Prostate CancerR01CA138642 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI DAHIYA, RAJVIR · 2010 to 2014
$2.6M
Chemo-dietary prevention, miRNAs, epigenetic and prostate cancerR01CA160079 · NCI · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI DAHIYA, RAJVIR · 2011 to 2015
$2.2M
Genistein and chemotherapy of kidney cancerR01CA196848 · NCI · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI YAMAMURA, SOICHIRO · 2016 to 2020
$1.7M
Molecular biomarkers for kidney cancer prognosis using non-coding RNAsR01CA199694 · NCI · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI TANAKA, YUICHIRO · 2016 to 2020
$1.7M
Genetic factors for race related prostate cancer.U01CA184966 · NCI · NORTHERN CALIFORNIA INSTITUTE/RES/EDU · PI DAHIYA, RAJVIR · 2015 to 2019
$1.6M
Role of genetic biomarkers in clinical assessment of prostate cancerIP1BX001604 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI DAHIYA, RAJVIR, LAU, YUN-FAI CHRIS · 2013 to 2016
–
BLR&D Research Career Scientist Award ApplicationIK6BX004473 · VA · VETERANS AFFAIRS MED CTR SAN FRANCISCO · PI DAHIYA, RAJVIR · 2019 to 2021
–
BLRD VA IK6 BX004473BLRD VA IP1 BX001604NCI NIH HHS R01 CA138642NCI NIH HHS R01 CA160079NCI NIH HHS R01 CA196848NCI NIH HHS R01 CA199694NCI NIH HHS U01 CA184966NIH HHS R01CA196848NIH HHS R01CA199694NIH HHS U01CA184966VA BX001604VA (Department of Veterans Affairs) BX001123VA (Department of Veterans Affairs) BX004473
6 · The paper itself

Abstract

BACKGROUND/

aimsGenistein, a soy isoflavone, has been shown to have anti-cancer effects in various cancers including renal cancer. Long non-coding RNA, HOX transcript antisense RNA (HOTAIR), is involved in cancer progression and metastasis, such as renal cancer. Our aim was to investigate the effects of genistein on HOTAIR chromatin remodeling functions.

methodsWe used MTS assays and Transwell migration assays to study the effects of genistein on cell proliferation and migration respectively in human renal cell carcinoma (RCC) cell lines. We used Western blots to analyze SNAIL and ZO-1 expression. We performed chromatin immunoprecipitation (ChIP) assays to study recruitment of the polycomb repressive complex 2 (PRC2) to the ZO-1 promoter. We performed RNA immunoprecipitation (RIP) assays to study interaction between HOTAIR and PRC2, SMARCB1 or ARID1A. We also performed transfection experiments to overexpress EED, HOTAIR and knockdown SMARCB1.

resultsGenistein reduced cell proliferation and migration of human renal cell carcinoma cell lines. ChIP assays indicated that genistein reduces recruitment of the PRC2 to the ZO-1 promoter and increased its expression. RIP assays showed that genistein inhibits HOTAIR interaction with PRC2, leading to tumor suppression. Immunoprecipitation also revealed that genistein reduced EED levels in PRC2, suggesting that decreased EED levels suppress HOTAIR interaction with PRC2. EED overexpression in the presence of genistein restored PRC2 interaction with HOTAIR and reduced ZO-1 transcription, suggesting genistein activates ZO-1 by inhibiting HOTAIR/PRC2 functions. RIP assays also showed that HOTAIR interacts with SMARCB1 and ARID1A, subunits of the human SWI/SNF chromatin remodeling complex and genistein reduces this interaction. Combination of HOTAIR overexpression and SMARCB1 knockdown in the presence of genistein revealed that genistein inhibits SNAIL transcription via the HOTAIR/SMARCB1 pathway.

conclusionGenistein suppresses EED levels in PRC2 and inhibits HOTAIR/PRC2 interaction. Genistein suppresses HOTAIR/PRC2 recruitment to the ZO-1 promoter and enhances ZO-1 transcription. Genistein also inhibits SNAIL transcription via reducing HOTAIR/SMARCB1 interaction. We demonstrate that the reduction of HOTAIR interaction with chromatin remodeling factors by genistein represses HOTAIR/chromatin remodeling pathways to suppress RCC malignancy.

Indexed as

Anticarcinogenic AgentsCell Line, TumorCell ProliferationChromatin Assembly and DisassemblyGene Expression Regulation, NeoplasticGenisteinHumansKidney NeoplasmsNeoplasm InvasivenessRNA, Long NoncodingAnticarcinogenic AgentsGenisteinHOTAIR long untranslated RNA, humanRNA, Long NoncodingGenisteinHOTAIRPRC2Renal cancerSMARCB1

Identifiers

PMID31961100
PMCPMC7382546
OpenAlexW3003362145

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.